Search details
1.
Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study.
Blood
; 143(8): 713-720, 2024 Feb 22.
Article
in English
| MEDLINE | ID: mdl-38085846
2.
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.
Blood
; 140(9): 980-991, 2022 09 01.
Article
in English
| MEDLINE | ID: mdl-35687757
3.
COVID-19 vaccine safety and immunogenicity in patients with cold agglutinin disease receiving concomitant sutimlimab.
Am J Hematol
; 99(4): 789-791, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38385639
4.
Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study.
Eur J Haematol
; 110(3): 280-288, 2023 Mar.
Article
in English
| MEDLINE | ID: mdl-36403132
5.
Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open-label, extension trial.
Br J Haematol
; 198(4): e59-e62, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35655238
6.
Sutimlimab, an investigational C1s inhibitor, effectively prevents exacerbation of hemolytic anemia in a patient with cold agglutinin disease undergoing major surgery.
Am J Hematol
; 97(2): E51-E54, 2022 02 01.
Article
in English
| MEDLINE | ID: mdl-34778998
7.
Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up.
Blood Adv
; 7(19): 5890-5897, 2023 10 10.
Article
in English
| MEDLINE | ID: mdl-37459203
8.
Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6-17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial.
Diabetes Care
; 43(7): 1512-1519, 2020 07.
Article
in English
| MEDLINE | ID: mdl-32430458
9.
Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial.
Diabetes Technol Ther
; 22(7): 516-526, 2020 07.
Article
in English
| MEDLINE | ID: mdl-32068436
10.
Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1).
Diabetes Technol Ther
; 22(2): 85-95, 2020 02.
Article
in English
| MEDLINE | ID: mdl-31804851
11.
Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes.
Diabetes Technol Ther
; 18(4): 252-7, 2016 Apr.
Article
in English
| MEDLINE | ID: mdl-26840338
12.
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.
Diabetes Care
; 39(8): 1318-28, 2016 Aug.
Article
in English
| MEDLINE | ID: mdl-27222510
13.
New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
Diabetes Care
; 37(12): 3235-43, 2014 Dec.
Article
in English
| MEDLINE | ID: mdl-25193531
Results
1 -
13
de 13
1
Next >
>>